Mass meeting

Complete Genomics and seqWell Announce Codevelopment Partnership at AGBT

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Genomics, Product management, SAN, Marketing, Complete Genomics, Completeness, Human genetics, DNA, Mass meeting, Society, NGS, Genomic library, Synthetic biology, ASHG

SAN JOSE, Calif. and BEVERLY, Mass., Feb. 7, 2024 /PRNewswire/ -- Complete Genomics, a life sciences company specializing in end-to-end DNA sequencing solutions, and seqWell, a global provider of genomic library preparation workflow solutions, today announced a partnership aimed at expanding the range of library preparation product offerings available to Complete Genomics customers. The companies will work together to ensure seqWell-developed products are compatible with the entire Complete Genomics next-generation sequencing (NGS) and automation portfolios.

Key Points: 
  • The companies will work together to ensure seqWell-developed products are compatible with the entire Complete Genomics next-generation sequencing (NGS) and automation portfolios.
  • "Our partnership with seqWell enables us to offer a broader range of tools to support a broader range of customer needs."
  • Leveraging the power of the Complete Genomics DNBSEQ-G400RS * and seqWell purePlex ™ DNA Library Prep Kit , this partnership will allow customers to the ability to run cost-effective and scalable workflows pairing seqWell library prep kits with Complete Genomics' portfolio of DNBSEQ technologies.
  • The latest outcome of this partnership enables customers to pair seqWell's ExpressPlex ™ library prep kits with Complete Genomics' portfolio of DNBSEQ technologies, including the DNBSEQ-G-99 RS* and DNBSEQ-T7 RS* sequencers.

Notice convening the Annual General Meeting of Valmet Oyj

Retrieved on: 
Wednesday, February 7, 2024
Language, Mass meeting, Exercise, Auditor, Section, EUR, Treasury, Webcast, Remuneration, Finance, Coffee, Annual, Chapter Five, Messukeskus Helsinki, KHT, Annual general meeting, Committee, Osakeyhtiö, Financial statement, Convention center, Policy, Report, Participation, Proxy, KRT, Investment, Audit committee, EET, Bank statement, Chapter Ten, Conference, Security (finance)

ESPOO, Finland, Feb. 7, 2024 /PRNewswire/ -- Notice is given to the shareholders of Valmet Oyj ("Valmet" or the "Company") to the Annual General Meeting to be held on March 21, 2024 starting at 1:00 p.m. (EET) at Siipi Conference Centre of Helsinki Expo and Convention Centre (Messukeskus Helsinki), hall 101 at the address Rautatieläisenkatu 3, 00520 Helsinki, Finland. The reception of the shareholders who have registered for the meeting and the distribution of voting tickets will commence at 12:00 noon.

Key Points: 
  • In addition, the shareholders who have registered for the meeting can follow the Annual General Meeting via a webcast.
  • For further instructions, please refer to Section C. "Instructions for the Participants in the Annual General Meeting" of this notice.
  • Valmet's Nomination Board proposes to the Annual General Meeting, that the number of members of the Board of Directors for the term expiring at the close of the Annual General Meeting 2025 be eight (8).
  • The Board of Directors proposes to the Annual General Meeting that the Annual General Meeting authorize the Board of Directors to resolve on the repurchase of the Company's own shares in one or several tranches.

At AGBT, Complete Genomics showcases expanded sequencing applications, talks from customers and collaborators on research powered by the DNBSEQ-T7 Sequencer

Retrieved on: 
Tuesday, February 6, 2024
Genomics, Metagenomics, SAN, Complete Genomics, Research, Mass meeting, CMOS, Environmental monitoring, Chemistry, MPS, HLA, Software, MRD, Standard, Q50, Genome, Antibiotics

SAN JOSE, Calif., Feb. 6, 2024 /PRNewswire/ -- Complete Genomics, a California-based life sciences company that provides novel, comprehensive sequencing solutions, today highlighted expanded sequencing applications enabled by DNBSEQ™-T7, a leading high- throughput sequencer which will be the subject of customer talks at the Advances in Genome Biology and Technology (AGBT) General Meeting.

Key Points: 
  • After four years in the field, the DNBSEQ-T7, or the T7, remains a leading sequencer in its class, due to its speed, accuracy and flexibility.
  • The T7 enables a wide range of applications such as CompleteWGS, a novel phased genome approach, spatial transcriptomics, cf-DNA sequencing for MRD and early detection, and single cell sequencing.
  • The DNBSEQ™-T20X2 is Complete Genomics' ultra-high-throughput sequencer for the most challenging projects, delivering efficient sequencing at less than $1 per Gigabase.
  • Highly accurate base calling and robust copy number correction is ensured by our robotics-enabled fluidics, which uses whole-wafer-sized slides.

Results of 2024 Extraordinary General Meeting

Retrieved on: 
Tuesday, February 6, 2024
CTH, ASX, TSX, Mass meeting, Corporation, XAM

TORONTO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) advises that as required by ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the results of Xanadu Mines Ltd’s 2024 Extraordinary General Meeting held today, are set out in the attached report and includes a summary of the poll voting results and votes by proxies on the items of business considered at the General Meeting.

Key Points: 
  • TORONTO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu or the Company) advises that as required by ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the results of Xanadu Mines Ltd’s 2024 Extraordinary General Meeting held today, are set out in the attached report and includes a summary of the poll voting results and votes by proxies on the items of business considered at the General Meeting.

Vizgen Kicks Off AGBT with Enhanced MERFISH Chemistry Updates and 2024 Product Roadmap Highlights

Retrieved on: 
Monday, February 5, 2024
Neurology, Health, Genetics, Science, Research, Partnership, RNA, Sunset Terrace/Montclair, Houston, Data management, Glass, Mass meeting, Gene, Brain, Gene expression profiling, BioRxiv, Biology, Software

Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.

Key Points: 
  • Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.
  • In addition to the announcement of these product developments, Vizgen will be presenting three posters at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting, in Orlando, Florida, this week.
  • The enhanced MERFISH chemistry will extend the best-in-class sensitivity of MERFISH to degraded RNA samples, including archival FFPE samples, enabling translational research.
  • Data demonstrating this superior detection capacity is expected to be released in the coming months, with plans to make the enhanced MERFISH chemistry available to users in the summer of 2024.

Vizgen and Scale Biosciences Unveil Strategic Partnership at AGBT

Retrieved on: 
Monday, February 5, 2024
Other Health, Software, Research, Oncology, Technology, Genetics, Health Technology, Science, Biotechnology, Neurology, Other Science, Health, Partnership, Poster, RNA, Sunset Terrace/Montclair, Houston, DNA, Spatial analysis, Mass meeting, Neuroscience, Data analysis, Neuron, Brain, Tissue, Workshop, DNA methylation, Microscope

Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced a partnership with Scale Biosciences (ScaleBio) to combine their single-cell and spatial technologies for enhanced data analysis at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida.

Key Points: 
  • Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced a partnership with Scale Biosciences (ScaleBio) to combine their single-cell and spatial technologies for enhanced data analysis at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting in Orlando, Florida.
  • As part of the strategic partnership, Vizgen and ScaleBio will leverage their respective technology to generate high resolution data from serial mouse brain tissue sections for single cell RNA-seq, single cell DNA methylation and targeted spatial gene expression.
  • Such data can then be leveraged for a variety of applications, including neuroscience and cancer biology,” said Terry Lo, President and CEO of Vizgen.
  • In addition, Vizgen will sponsor a Women’s Networking Event on Tuesday, February 6, from 5:15 – 7:15 p.m.

Ultima Genomics to Launch UG 100™ System and Present Data at AGBT

Retrieved on: 
Monday, February 5, 2024
Biotechnology, Health, Genetics, Health Technology, Oncology, Flex, Genomics, Next wave, DNA, Ultima, Broad, Mass meeting, Harvard University, Regeneron Pharmaceuticals, Weill Cornell Medicine, Methylation, Lunch, Genome informatics, MIT, Physiology, Cancer, Genome, Antibiotics

Ultima Genomics, Inc. , a developer of a revolutionary new ultra-high throughput sequencing architecture, will present product and commercial launch details for the UG 100™ system as the Gold Sponsor at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL.

Key Points: 
  • Ultima Genomics, Inc. , a developer of a revolutionary new ultra-high throughput sequencing architecture, will present product and commercial launch details for the UG 100™ system as the Gold Sponsor at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL.
  • The Gold Sponsor workshop will also include presentations by customers and collaborators from multiple leading institutions including:
    Stacey Gabriel, Ph.D., Executive Vice President of Platforms and Scientific Execution, Institute Scientist, Broad Institute of MIT and Harvard
    Aziz Al’Khafaji, Ph.D., Associate Director, Technology Development – Genomics Platform, Broad Institute of MIT and Harvard
    Will Salerno, Ph.D., Executive Director of Genome Informatics & Data Engineering, Regeneron Pharmaceuticals
    Dan Landau, M.D., Ph.D., Professor of Physiology and Biophysics, Weill Cornell Medical College
    Join Ultima for a series of talks and poster sessions, including:
    Ultima Genomics will be hosting the Gold Sponsor Workshop and Lunch entitled “Genomics unleashed: the $100 genome and beyond” at 12:00 pm in Grand Sierra Ballroom D&E
    Ultima technology will be featured in three posters during the Tuesday poster session at 1:30 pm in Palms Ballroom I:
    101 - Advancing cancer genomics with cost-effective whole genome sequencing: somatic variant calling using the UG 100 platform,​ by Hila Benjamin of Ultima Genomics
    518 - A continued evaluation of the Ultima Genomics UG100 platform: operational advancements and new methods for ancient DNA, single-cell, and methylation applications, by Matthew Coole of the Broad Institute
    592 - Integration of mostly-natural sequencing by synthesis with multiple single cell and spatial assays: 10X Flex, Visium and immune profiling,​ by Gila Yanai of Ultima Genomics
    Ultima Genomics will be hosting a Technical Breakfast Workshop entitled “Introducing a New Era: Part Per Million Detection Accuracy with ppmSeq™️ Technology” at 8:00 am in Ultima Suite, Grand Sierra Ballroom C
    Ultima technology will be featured in three posters during the Wednesday poster session at 4:45 pm in Palms Ballroom I:
    557 - Assessment of Ultima Genomics $100 genome for whole genome sequencing-based cancer diagnostics, by Edwin Cuppen of the Hartwig Medical Foundation
    625 - Scalable Dual Indexed Single Cell WGS on Ultima Genomics, ​ by Andrew Wicks of the New York Genome Center​
    Ultima Genomics will be hosting a Technical Breakfast Workshop entitled “Introducing the Next Wave of Single Cell and Omics at Scale” at 8:00 am in Ultima Suite, Grand Sierra Ballroom C

10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting

Retrieved on: 
Monday, February 5, 2024
Flex, Genomics, Growth, Glossary of biology, Cell, Cytokine, B cell, Mass meeting, Transcriptome, Gene expression, Protein, Biology, Tissue, CRISPR, Chromium, Multimodal, Microscope

PLEASANTON, Calif., Feb. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT) General Meeting this week in Orlando, Florida.

Key Points: 
  • "The new products we have planned for 2024 will take 10x to the next level, as we deliver game-changing new technologies that will redefine the Visium, Xenium and Chromium platforms," said Ben Hindson, Co-founder and Chief Scientific Officer of 10x Genomics.
  • 10x Genomics will host a workshop at AGBT on Wednesday, February 7, at 1:10 p.m.
  • At AGBT, 10x Genomics will unveil new products, features and protocols designed to enable researchers with improved and more cost effective single cell workflows.
  • Throughout AGBT, 10x Genomics will demonstrate the use of its platforms to generate groundbreaking biological insights:
    Sponsor Workshop: Mind blowing science enabled by industry-leading single cell & spatial technologies (February 7, 2024).

Element to Present Data on New Products and Multi-Omics Capabilities at AGBT

Retrieved on: 
Monday, February 5, 2024
ABC, Tavarua, SAN, Workflow, Multi, RNA, Science, Research, Agriculture, DNA, Mass meeting, Gene, Biomedicine, Systems biology, Informatics, SVP, UC, Protein, Computational biology, HD, Learning, Biomedical engineering, Cancer, Endothelium, Doctor of Philosophy, Element, Q50, Leukemia

Never before have so many data points been available to researchers at this cost and speed.

Key Points: 
  • Never before have so many data points been available to researchers at this cost and speed.
  • Cloudbreak UltraQ is the industry's first commercial Q50 kit capable of generating 100-fold higher accuracy than currently available published specifications.
  • Trinity is Element's on-board enrichment solution that simplifies targeted sequencing, to provide users with a new level of convenience, flexibility, and performance.
  • AVITI24 streamlines these studies and data collection to enable rapid recursive learning with broad applications across systems biology.

Kaufman & Broad SA: ANNUAL RESULTS 2023

Retrieved on: 
Monday, February 5, 2024
Shareholder, Mass meeting, Environment, Housing, Marketing, Real estate, ABIS, Commercial, Corporation, Acquisition, KB Home, Fitch, Bond credit rating, Share repurchase, Minority, Backlog, Apartment, VAT, Cryptocurrency

Main elements of commercial activity (2023 vs. 2022)

Key Points: 
  • Main elements of commercial activity (2023 vs. 2022)
    Main financial items (2023 vs. 2022 unless otherwise specified)
    EBIT margin(c): 7.8 % vs. 7.5%
    Net cash (b) : €180.5M vs. € (67.8 ) M at 30 Nov 2022
    Main development indicators (end of Nov. 2023 vs. end of Nov. 2022)
    Kaufman & Broad SA today announces its 2023 results (from December 1st to November 30th, 2023).
  • Nordine Hachemi, Chairman and Chief Executive Officer of Kaufman & Broad, said:
    “Kaufman & Broad's 2023 results are in line with guidance.
  • In this environment, Kaufman & Broad continued to apply a rigorous policy of rapid adjustment to market conditions.
  • Last September, Fitch confirmed the Investment Grade rating of Kaufman & Broad SA, the only European developer to have this rating.